MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.77
-0.55
-8.70%
After Hours: 5.79 +0.02 +0.35% 16:32 12/06 EST
OPEN
6.08
PREV CLOSE
6.32
HIGH
6.10
LOW
5.51
VOLUME
5.06M
TURNOVER
--
52 WEEK HIGH
24.90
52 WEEK LOW
4.862
MARKET CAP
722.81M
P/E (TTM)
-10.6852
1D
5D
1M
3M
1Y
5Y
Jim Cramer is Bearish on These 10 Stocks
In this article, we discuss the 10 stocks that Jim Cramer is bearish on. If you want to skip our detailed analysis of these stocks, go directly to Jim Cramer is Bearish on These 5 Stocks. Jim Cramer, the finance expert who hosts Mad Money on CNBC, has deve...
Insider Monkey · 3d ago
Oral Covid vaccine hopeful buys 2nd manufacturing facility
The South San Francisco company, which has expanded its real estate footprint this year, had been working with Kindred Biosciences since spring 2020 on manufacturing its experimental Covid vaccine tablet.
American City Business Journals · 5d ago
Cramer Gives His Opinion On Nokia, Delta Air Lines And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DigitalOcean Holdings, Inc. (NYSE: DOCN) is in the right place and he has always liked these kinds of firms. "It’s a very high multiple stock, and that’s what’s causing the decline," he said.
Benzinga · 5d ago
BRIEF-Vaxart Inc To Purchase Kindredbio's Manufacturing Equipment And Sublease Of Its GMP Manufacturing Facility In Burlingame
reuters.com · 5d ago
Vaxart acquires second GMP manufacturing facility
Vaxart (NASDAQ:VXRT) has announced the acquisition of its second GMP manufacturing facility. The clinical-stage biotechnology company entered into an agreement with Kindred Bioscience for the purchase of KindredBio's manufacturing equipment
Seekingalpha · 5d ago
Vaxart Reports Purchase Of Its Second Good Manufacturing Practices Manufacturing Facility, No Terms Disclosed
Vaxart, Inc. (NASDAQ:VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good
Benzinga · 5d ago
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
Purchase expected to give Vaxart greater control over manufacturing schedules...
Globe Newswire · 5d ago
Cramer's lightning round: You can buy a little Delta Air Lines now
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of VAXART through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VXRT stock price target is 13.00 with a high estimate of 18.00 and a low estimate of 9.00.
High18.00
Average13.00
Low9.00
Current 5.77
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 163
Institutional Holdings: 38.51M
% Owned: 30.74%
Shares Outstanding: 125.27M
TypeInstitutionsShares
Increased
46
3.74M
New
18
505.79K
Decreased
38
1.30M
Sold Out
17
274.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.95%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Non-Executive Chairman/Independent Director
Wouter Latour
President/Chief Executive Officer/Chief Financial Officer/Director
Andrei Floroiu
Senior Vice President/Chief Accounting Officer
Margaret Echerd
Senior Vice President/Chief Scientific Officer
Sean Tucker
Independent Director
Julie Cherrington
Independent Director
Todd Davis
Independent Director
Michael Finney
Independent Director
David Wheadon
Independent Director
Karen Wilson
Independent Director
Robert Yedid
Declaration Date
Dividend Per Share
Ex-Div Date
10/25/2012
Dividend USD 1.108
11/09/2012
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company. It is focused on developing oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and will be useful for the treatment of chronic viral infections and cancer. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). It is also developing therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV). Its therapeutic oral vaccine candidate targets HPV-16 and HPV-18, the two strains responsible for cervical cancers and precancerous cervical dysplasia. It uses a short section of double-stranded ribonucleic acid RNA (dsRNA) as an adjuvant to improve the immunogenicity of its tablet vaccine candidates.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.